AG真人官方

Cannabix Technologies Commences First Production of BreathLogix Alcohol Screening Devices

VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 鈥淐ompany or Cannabix鈥�) developer of marijuana and alcohol breath devices is pleased to report that it has directed Price Electronics to begin manufacturing BreathLogix alcohol screening device components for an initial commercial production run.

The Company recently selected Price Industries Ltd. (鈥淧rice Electronics鈥�) as contract manufacture for its BreathLogix alcohol screening device product lines because they are a well-established contract manufacturer with ISO 13485 (medical devices qualifications), ISO9001 and IPC certifications. Price Electronics has a 28,000 square foot manufacturing facility located in Winnipeg, MB, that can cost-effectively support a full range of production volumes and product technologies with scalability.

The Company has provided Price Electronics specifications and tolerances for its BreathLogix alcohol screening device and Price Electronics has begun manufacturing components for assembly and quality control by Cannabix.

The BreathLogix 鈥淲orkplace Series鈥� device was approved by National Highway Traffic Safety Association (in the United States) to be added to the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screen devices.

The Company recently entered into an exclusive distribution and sales agreement with Breathalyser Sales & Service Pty Ltd., for Australia, New Zealand and the Pacific Islands.

We seek Safe Harbor.

On behalf of the Board of Directors

鈥淩av Mlait鈥�

CEO
Cannabix Technologies Inc.

For further information, contact the Company at [email protected]听

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies; positive developments with contract manufacturers; the completion of pre-validation or validation testing; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors and or contract manufacturers; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company鈥檚 plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company鈥檚 development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 鈥減atent pending鈥� or 鈥減rovisional patents鈥� technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.